Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well oxaloacetate works in reducing cognitive complaints in
stage 0-IIIA breast cancer survivors. Oxaloacetate is a natural substance found in the body
and is available as a nutritional supplement. Giving oxaloacetate may reduce inflammation in
the brain that could be contributing to cognitive complaints seen after cancer treatments.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Breast Cancer Research Foundation MetVital, Inc. National Cancer Institute (NCI)